Erratum to: Wasting in chronic kidney disease (J Cachexia Sarcopenia Muscle, (2011), 2, (9-25), 10.1007/s13539-011-0019-5);Wasting in chronic kidney disease

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 1, 2011, Pages 9-25

  Mak, Robert H ^a,b   Ikizler, Alp T ^c   Kovesdy, Csaba P ^d,e   Raj, Dominic S ^f   Stenvinkel, Peter ^g   Kalantar Zadeh, Kamyar ^h,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h HARBOR UCLA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic; Kidney disease; Wasting

Indexed keywords

BORAGE OIL; BORTEZOMIB; C REACTIVE PROTEIN; CHOLESTEROL; FISH OIL; GAMMA INTERFERON; GHRELIN; HEMOGLOBIN; HUMAN GROWTH HORMONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MEGESTROL ACETATE; MELANOCORTIN; PREALBUMIN; SERUM ALBUMIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADRENAL INSUFFICIENCY; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ARM CIRCUMFERENCE; BODY FAT; BODY MASS; CACHEXIA; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONFUSION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DIZZINESS; DRUG INDUCED HEADACHE; ENERGY EXPENDITURE; EXERCISE; FATIGUE; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; GROWTH DISORDER; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; METABOLIC ACIDOSIS; MORTALITY; MUSCLE ATROPHY; MUSCLE WEAKNESS; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTAKE; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; UTERUS BLEEDING; VITAMIN D DEFICIENCY; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 79958150806     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0026-6     Document Type: Erratum

References (141)

1. Kopple JD. McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance hemodialysis patients. Am J Clin Nutr. 1996; 65: 1544-57.
2. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequence. Am J Kidney Dis. 2003; 42: 864-81.
3. World Health Organization. Wasting... stunting. World Health Organization. 1988; 10-3, May.
4. Cheung WW, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest. 2005; 115: 1659-65.
5. Mak RH, Cheung W. Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol. 2006; 21: 1807-14.
6. Mak RH, Cheung W, Cone RD, Marks DL. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int. 2006; 69: 794-7.
7. Mak RH, Cheung W, Cone RD, Marks DL. Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. Nat Clin Pract Nephrol. 2006; 2: 527-34.
8. Cheung WW, Mak RH. Ghrelin in chronic kidney disease. Int J Pept 2010; pii: 567343.
9. Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol. 2010; 25: 711-24.
10. Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. J Am Soc Nephrol. 2002; 13 Suppl 1: S22-27.
11. Mitch WE. Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest. 2002; 110: 437-9.
12. Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr. 2006; 16: 208-11.
13. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004; 80: 299-307.
14. Sea WAY, MM TN, Sanderson JE, Lui SG, Li PK, Woo J. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol. 2004; 15: 3134-43.
15. Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int. 2004; 66: 2054-60.
16. Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, et al. Association of malnutrition-inflammation score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis. 2009; 53: 298-309.
17. Devereaux PJ, Schunemann HJ, Ravindran N, Bhandari M, Garg AX, Choi PT, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA. 2002; 288: 2449-57.
18. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med. 2004; 351: 1296-305.
19. Mak RH, Cheung W. Therapeutic strategy for cachexia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2007; 16: 542-6.
20. Cano NJ, Fouque D, Roth H, Aparicio M, Azar R, Canaud B, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol. 2007; 18: 2583-91.
21. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008; 27: 793-9.
22. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008; 73: 391-8.
23. Bozzetti F, Mariani L. Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. J Parent Enteral Nutr. 2009; 33: 361-7.
24. Freeman DS, Ogden CL, Berenson GS, Horlick M. Body mass index and body fatness in childhood. Curr Opin Clin Nutr Metab Care. 2005; 8: 618-23.
25. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005; 81: 543-54.
26. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Clin Nutr. 1998; 31: 997-1006.
27. Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, et al. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis. 2000; 36: 811-9.
28. Stenvinkel P, Heimburger O, Lindholm B. Wasting, but not malnutrition, predicted cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant. 2004; 19: 2181-3.
29. Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB, et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5: 2258-68.
30. Bross R, Chandramohan G, Kovesdy CP, Oreopoulos A, Noori N, Golden S, et al. Comparing body composition assessment tests in long-term hemodialysis patients. Am J Kidney Dis. 2010; 55: 885-96.
31. Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr. 2006; 83: 202-10.
32. Noori N, Kovesdy CP, Dukkipati R, Kim Y, Duong U, Bross R, et al. Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis. Am J Clin Nutr. 2010; 92: 1060-70.
33. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimbürger O, Axelsson J, Bárány P, et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant. 2010; 25: 562-8.
34. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr. 2007; 85: 695-701.
35. Shinaberger CS, Kilpatrick RD, Regidor DL, McAllister CJ, Greenland S, Kopple JD, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kid Dis. 2006; 48: 37-49.
36. Betts P, Magrath G. Growth pattern and dietary intake of children with chronic renal insufficiency. BMJ. 1974; 2: 189-93.
37. Abitbol CL, Zilleruelo G, Montane B, Strauss J. Growth of uremic infants on forced feeding regimens. Pediatr Nephrol. 1993; 7: 173-7.
38. Owen Jr WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993; 329: 1001-6.
39. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis. 2002; 40: 721-7.
40. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn Jr H, Kopple JD, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005; 20: 1880-8.
41. Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr. 2009; 90: 407-14.
42. Kato A, Takita T, Furuhashi M, Maruyama Y, Hishida A. Comparison of serum albumin, C-reactive protein and carotid atherosclerosis as predictors of 10-year mortality in hemodialysis patients. Hemodial Int. 2010; 14: 226-32.
43. Wong CS, Hingorani S, Gillen DL, Sherrad DJ, Watkins SL, Brandt JR, et al. Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease. Kidney Int. 2002; 61: 630-7.
44. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol. 2009; 29: 3-14.
45. National Kindey Foundation: Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI. Am J Kidney Dis. 2000; 35(Suppl 2): S1-140.
46. Lacson Jr E, Wang W, Hakim RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis. 2009; 53: 79-90.
47. Lacson Jr E, Wang W, Lazarus JM, Hakim RM. Hemodialysis facility-based quality-of-care indicators and facility-specific patient outcomes. Am J Kidney Dis. 2009; 54: 490-7.
48. Rambod M, Kovesdy CP, Bross R, Kopple JD, Kalantar-Zadeh K. Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am J Clin Nutr. 2008; 88: 1485-94.
49. Kalantar-Zadeh K, Kleiner M, Dunne E, Ahern K, Nelson M, Koslowe R, et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis. 1998; 31: 263-72.
50. Bross R, Zitterkoph J, Pithia J, Benner D, Rambod M, Kovesdy CP, et al. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol. 2009; 29: 571-81.
51. Steiber AL, Kalantar-Zadeh K, Secker D, McCarthy M, Sehgal A, McCann L. Subjective global assessment in chronic kidney disease: a review. J Ren Nutr. 2004; 14: 191-200.
52. De Mulsert R, Brootendorst DC, Axelsson J, Boeschoten EW, Krediet RT, Dekker FW, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008; 23: 2957-64.
53. Bellisle F, Dartois AM, Kleinknecht C, Broyer M. Alteration of the taste for sugar in renal insufficiency: study in the child. Néphrologie. 1995; 16: 203-8.
54. Hung KC, Wu CC, Chen HS, Ma WY, Tseng CF, Yang LK, et al. Serum IL-6, albumin and co-morbidities are closely correlated with symptoms of depression in patients on maintenance hemodialysis. Neph Dial Transplant. 2010. doi: 10. 1093/ndt/gfq411.
55. Mak RH, Cheung W, Purnell J. Ghrelin in chronic kidney disease: too much or too little? Perit Dial Int. 2007; 27: 51-5.
56. Daschner M, Tonshoff B, Blum WF, Englaro P, Wingen AM, Schaefer F, et al. Inappropriate elevation of serum leptin levels in children with chronic renal failure. European study group for nutritional treatment of chronic renal failure in children. J Am Soc Nephorl. 1998; 9: 1074-9.
57. Cheung WW, Huo HJ, Markison S, Chen C, Foster AC, Marks DL, et al. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J Am Soc Nephrol. 2007; 18: 2517-24.
58. Rodriguez-Carmona A, Perez Fontan M, Cordido F, Garcia Falcon T, Garcia-Buela J. Hyperleptinemia is not correlated with markers of protein malnutrition in chronic renal failure. A cross-sectional study in predialysis, peritoneal dialysis and hemodialysis patients. Nephron. 2000; 86: 274-80.
59. Bossola M, Muscaritoli M, Valenza V, Panocchia N, Tazza L, Cascino A, et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin Pract. 2004; 97: c76-82.
60. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol. 2000; 11: 1303-9.
61. Yoshimoto A, Mori K, Sugawara A, Mukovama M, Yahata K, Suganami T, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Plasma ghrelin and desacyl ghrelin concentration in renal failure. J Am Soc Nephrol. 2002; 13: 2748-52.
62. Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004; 19: 2095-100.
63. Szczepanska M, Szprynger K, Mazur B, Zwolinska D, Killis-Pstrusinska K, Makulska I. Plasma ghrelin levels in children with chronic renal failure on peritoneal dialysis. Perit Dial Intl. 2007; 27: 61-6.
64. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Codoceo R, Alvarez-Fidalgo P, Bajo MA, et al. Serum ghrelin concentration in patients with chronic renal failure undergoing dialysis. Clin Endocrinol. 2006; 64: 68-73.
65. Hosoda H, Kojima M, Matsuo H, Kangewa K. Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem. 2000; 275: 21995-2000.
66. Hosoda H, Kojima M, Matsuo H, Kangewa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Comm. 2000; 279: 909-13.
67. Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Garcia-Naveiro R, Isidro ML, Villaverde P, et al. Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney Int. 2005; 68: 2877-85.
68. Ayala ER, Pecoits-Filho R, Heimburger O, Lindholm B, Nordfors L, Stenvinkel P. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant. 2004; 19: 421-6.
69. Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Kangawa K. Separate measurement of plasma levels in acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab. 2005; 90: 6-9.
70. Utaka S, Avesani CM, Draibe SA, Kamimura MA, Andreoni S, Cuppari L. Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. Am J Clin Nutr. 2005; 82: 801-5.
71. Argiles JM, Busquets S, Lopez-Sorian FJ. The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun. 2002; 293: 1145-52.
72. Hansen ES, Knudsen J. Parallel measurements of heat production and thermogenin content in brown fat cells during cold acclimation of rats. Biosci Rep. 1986; 6: 31-8.
73. Rothwell NJ, Stock MJ. A role for brown adipose tissue in diet-induced thermogenesis. Nature. 1979; 281: 31-5.
74. Raj DS, Adeniyi O, Dominic EA, Boivin MA, McClelland S, Tzamaloukas AH, et al. Amino acid repletion does not decrease muscle protein catabolism during hemodialysis. Am J Physiol Endocrinol Metab. 2007; 292: E1534-42.
75. Raj DS, Moseley P, Dominic EA, Onime A, Tzamaloukas AH, Boyd A, et al. Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Kidney Int. 2008; 73: 1054-61.
76. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest. 2004; 113: 115-23.
77. Boivin MA, Battah SI, Dominic EA, Kalantar-Zadeh K, Ferrando A, Tzamaloukas AH, et al. Activation of caspase-3 in the skeletal muscle during haemodialysis. Eur J Clin Invest. 2010; 40: 903-10.
78. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int. 2008; 74: 180-6.
79. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin Jr AS. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000; 289: 2363-6.
80. Ladner KJ, Caligiuri MA, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem. 2003; 278: 2294-303.
81. Storz P, Döppler H, Wernig A, Pfizenmaier K, Müller G. TNF inhibits insulin induced STAT5 activation in differentiated mouse muscle cells pmi28. FEBS Lett. 1998; 440: 41-5.
82. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J. 2001; 15: 1169-80.
83. Cai D, Frantz JD, Tawa Jr NE, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004; 119: 285-98.
84. Hu Z, Wang H, Lee IH, Du J, Mitch WE. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest. 2009; 119: 3059-69.
85. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004; 20: 61-86.
86. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004; 350: 2682-8.
87. Kuninger DT, Rotwein PS. IGF action and skeletal muscle. In: LeRoith D, Zumkeller W, Baxter R, editors. Insulin-like growth factors. New York: Landes Bioscience; Kluwer Academic/Plenum; 2003. p. 235-43.
88. Mak RH, Rotwein P. Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation. Kidney Int. 2006; 70: 410-2.
89. Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-I and myostatin gene expression in uremia. Kidney Int. 2006; 70: 453-9.
90. Slew ED, Ikizler TA. Dietary concerns in advanced chronic kidney disease: insulin resistance and protein energy metabolism in advanced chronic kidney disease. Semin Nephrol. 2007; 23: 378-82.
91. Pupim LB, Flakoll PJ, Majchrzak KM, Aftab Guy DL, Stenvinkel P, Ikizler TA. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int. 2005; 68: 1857-65.
92. Pupim LB, Heimburger O, Qureshi AR, Ikizler TA, Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int. 2005; 68: 2368-74.
93. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int. 2007; 71: 146-52.
94. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol. 2004; 15: 1537-45.
95. Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int. 2009; 75: 961-8.
96. Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance and kidney function in the Third National and Health Examination Survey. Kidney Int. 2007; 71: 134-9.
97. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980; 209: 823-5.
98. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986; 119: 84-90.
99. Mak RH. 1, 25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998; 53: 1353-7.
100. Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int. 1998; 54: 603-7.
101. Caglar K, Fedje L, Dimmitt R, Hakim RM, Shyr Y, Ikizler TA. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int. 2002; 262: 1054-9.
102. Cockram DB, Hensley MK, Rodriguez M, Agarwal G, Wennberg A, Ruey P, et al. Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. J Ren Nutr. 1998; 8: 25-33.
103. Kalantar-Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr. 2005; 15: 318-31.
104. Sundell MB, Cavanaugh KL, Wu P, Shintani A, Hakim RM, Ikizler TA. Oral protein supplementation alone improves anabolism in a dose-dependent manner in chronic hemodialysis patients. J Ren Nutr. 2009; 19: 412-21.
105. Volpi E, Lucidi P, Cruciani G, Monacchia F, Reboldi G, Brunetti P, et al. Contribution of amino acids and insulin to protein anabolism during meal absorption. Diabetes. 1996; 45: 1245-52.
106. Ikizler TA. Nutrition support for the chronically wasted or acutely catabolic chronic kidney disease patient. Semin Nephrol. 2009; 29: 75-84.
107. Allman MA, Stewart PM, Tiller DJ, Horvath JS, Duggin GG, Truswell AS. Energy supplementation and the nutritional status of hemodialysis patients. Am J Clin Nutr. 1990; 51: 558-62.
108. Milano MC, Cusumano AM, Navarro ET, Turin M. Energy supplementation in chronic hemodialysis patients with moderate and severe malnutrition. J Ren Nutr. 1998; 8: 212-7.
109. Kuhlmann MK, Schmidt F, Kohler H. High protein/energy vs. standard protein/energy nutritional regimen in the treatment of malnourished hemodialysis patients. Miner Electrolyte Metab. 1999; 25: 306-10.
110. Patel MG, Kitchen S, Miligan PJ. The effect of dietary supplements on the npcr in stable hemodialysis patients. J Ren Nutr. 2000; 10: 69-75.
111. Hiroshige K, Sonta T, Suda T, Kanegae K, Ohtani A. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant. 2001; 16: 1856-62.
112. Leon JB, Albert JM, Gilchrist G, Kushner I, Lerner E, Mach S, et al. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am J Kidney Dis. 2006; 48: 28-36.
113. Fouque D, McKenzie J, de Mutsert R, Azar R, Teta D, Plauth M, et al. Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant. 2008; 23: 2902-10.
114. Secker D, Mak RH. Nutritional challenges in pediatric chronic kidney disease. In: Schaefer G, editor. Comphrehensive pediatric nephrology. Mosby: Philadelphia; 2008. p. 743-59.
115. Sienna JL, Saqan R, Teh JC, Frieling ML, Secker D, Cornelius V, et al. Body size in children with chronic kidney disease after gastrostomy tube feeding. Pediatr Nephrol. 2010; 25: 2115-21.
116. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol. 2006; 17: 2307-14.
117. Cheema B, Abas H, Smith B, O'Sullivan A, Chan M, Patwardhan A, et al. Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol. 2007; 18: 1594-601.
118. Kopple JD, Wang H, Casaburi R, Fournier M, Lewis MI, Taylor W, et al. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol. 2007; 18: 2975-86.
119. Pupim LB, Flakoll PJ, Levenhagen DK, Ikizler TA. Exercise augments the acute anabolic effects of intradialytic parenteral nutrition in chronic hemodialysis patients. Am J Physiol Endocrinol Metab. 2004; 286: E589-97.
120. Majchrzak KM, Pupim LB, Flakoll PJ, Ikizler TA. Resistance exercise augments the acute anabolic effects of intradialytic oral nutritional supplementation. Nephrol Dial Transplant. 2008; 23: 1362-9.
121. Dong J, Sundell MB, Pupim LB, Wu P, Shintani A, Ikizler TA (2010). The effect of resistance exercise to augment long-term benefits of intradialytic oral nutritional suppmentation in chronic hemodialysis patients. J Ren Nutr.
122. Burrowes JD, Bluestone PA, Wang J, Pierson RN. The effects of a moderate dose of megestrol acetate on nutritional status and body composition in a hemodialysis patient. J Ren Nutr. 1999; 9: 89-94.
123. Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr. 2000; 10: 36-43.
124. Caso G, Garlick PJ. Control of muscle protein kinetics by acid-base balance. Curr Opin Clin Nutr Metab Care. 2005; 8: 73-6.
125. Stein A, Moorhouse J, Iles-Smith H. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int. 1997; 52: 1089-95.
126. Pickering WP, Price SR, Bircher G, Nutrition in CAPD, et al. Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int. 2002; 61: 1286-92.
127. De Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009; 20: 2075-84.
128. Pupim LB, Flakoll PJ, Yu C, Ikizler TA. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr. 2005; 82: 1235-43.
129. Garibotto G, Barreca A, Russo R. Effects of recombinant growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest. 1997; 99: 97-105.
130. Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life and cardiovascular risk. J Am Soc Nephrol. 2007; 18: 2161-71.
131. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, et al. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. C J Am Soc Nephrol. 2008; 3: 1741-51.
132. Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G, Ghatei MA, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol. 2005; 16: 2111-8.
133. Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Bushbridge M, et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int. 2009; 76: 199-206.
134. DeBoer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology. 2008; 149: 827-35.
135. Chen C, Jiang W, Tucci F, Tran JA, Fleck BA, Hoare SR, et al. Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia. J Med Chem. 2007; 50: 5249-52.
136. Mitch WE, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome system. New Engl J Med. 1996; 335: 1897-905.
137. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4: 349-60.
138. Rocco MV, Dwyer JT, Larive B, Greene T, Cockram DB, Chumlea WC, et al. Kidney Int. 2004; 65: 2321-34.
139. Galland R, Traegar J, Arkouche W, Cleaud C, Delawari E, Fouque D. Short daily hemodialysis rapidly improves nutritional status. Kidney Int. 2001; 60: 1555-60.
140. FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. In center hemodialysis six times a week versus threee times a week. N Engl J Med. 2010; 363: 2287-300.
141. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010; 1: 7-8.